Mossrock Capital

Thomas Malley serves as President and Managing Member of Mossrock Capital and is the sole investment decision-maker based on all available public records. He is not known to employ a separate investment committee or delegated CIO structure. His investment judgment is shaped by two decades of biotech boardroom experience, most notably his long tenure on the board of BeiGene, the global oncology company co-founded by John V. Oyler.

Mossrock Capital pursues a concentrated, generalist mandate with a pronounced tilt toward biotechnology and healthcare. Public filings show positions in clinical-stage oncology companies, while Altss research identifies executive relationships with firms like Kiniksa Pharmaceuticals. Outside of life sciences, the firm holds real estate development projects in Philadelphia and residential property in Colorado. The strategy is not bound by a stated asset-allocation framework.

Mossrock Capital is classified as an asset manager in Altss research, though its structure — a single principal investing permanent capital without external fund vehicles — shares characteristics with a single family office. Thomas Malley does not market the firm to outside investors or operate commingled funds. The firm's Englewood, Colorado headquarters and Malley's sole decision-making authority support the view that this is a proprietary capital vehicle.

The specific wealth origin has not been publicly disclosed. Thomas Malley's professional biography centers on his investment career and biotechnology board service rather than an operating-company exit or inherited fortune. His long-term board role at BeiGene, which grew from a startup to a multi-billion-dollar market-cap oncology company, represents a significant professional association but has not been explicitly cited as the source of Mossrock's capital.

Available public records point exclusively to direct investments — public equity warrant positions, private biotech allocations, and real estate holdings — with no evidence of fund-of-funds commitments or allocations to external managers. Thomas Malley's boardroom relationships and BIO network suggest a sourcing model built on direct access to founder-led life-science ventures rather than intermediated fund structures.

The relationship is professional, not structural. Thomas Malley served on BeiGene's board of directors during the company's evolution from a preclinical oncology startup to a publicly traded biopharmaceutical firm on NASDAQ. BeiGene co-founder John V. Oyler is identified in Altss research as a long-term business partner of Malley. There is no evidence that Mossrock Capital itself holds any ownership stake in BeiGene or operates as its affiliated investment vehicle.

Thomas Malley and his wife Elaine Weng support Project C.U.R.E., the Denver-based organization that distributes donated medical supplies and equipment to under-resourced hospitals globally, and Malley holds membership in the President's Circle at California State University Channel Islands. These activities appear to be personal, not administered through a named private foundation linked to Mossrock Capital in public records.